Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02722954
Title A Study of Demcizumab Plus Pembrolizumab +/- Chemotherapy
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors OncoMed Pharmaceuticals, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA | GBR


No variant requirements are available.